NIH

NIH halts rivaroxaban arm in major stroke trial

February 13, 2026

National Institutes of Health (NIH) has halted the low‑dose rivaroxaban arm of the CAPTIVA (NCT05047172) stroke prevention trial after a routine review by the Data Safety and Monitoring Board detected increased safety events and a futility signal, indicating the regimen was unlikely to provide benefit. Rivaroxaban, an FDA‑approved anticoagulant, was being tested with aspirin to prevent recurrent stroke in adults with severe intracranial arterial stenosis.

All active participants in the discontinued arm have been instructed to stop treatment, while the remainder of the trial continues with the other therapy groups.

Source:

(2026, February 10). National Institutes of Health. NIH halts arm of clinical trial evaluating a potential stroke treatment. https://www.nih.gov/news-events/news-releases/nih-halts-arm-clinical-trial-evaluating-potential-stroke-treatment